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Objectives
To explore if duration of previous exposure to androgen
deprivation therapy (ADT) in men with prostate cancer
(PCa) undertaking a year-long exercise programme moderates
the exercise response with regard to body composition and
muscle performance, and also to explore the moderator
effects of baseline testosterone, time since ADT, and baseline
value of the outcome.
Patients and Methods
In a multicentre randomized controlled trial, 100 men who
had previously undergone either 6 months (short-term) or
18 months (long-term) of ADT in combination with
radiotherapy, as part of the TROG 03.04 RADAR trial,
were randomized to 6 months supervised exercise, followed
by a 6-month home-based maintenance programme, or to
printed physical activity educational material for 12 months
across 13 university-affiliated exercise clinics in Australia
and New Zealand. The participants were long-term
survivors of PCa with a mean age of 71.7  6.4 years, and
were assessed for lower extremity performance (repeated
chair rise), with a subset of men (n = 57) undergoing
additional measures for upper and lower body muscle
strength and body composition (lean mass, fat mass,
appendicular skeletal muscle [ASM]) by dual X-ray
absorptiometry. Data were analysed using generalized
estimating equations.
Results
Time on ADT significantly moderated the exercise effects on
chair rise (binteraction = 1.3 s, 95% confidence interval [CI]
2.6 to 0.0), whole-body lean mass (binteraction = 1194 g, 95%
CI 234 to 2153) and ASM mass (binteraction = 562 g, 95% CI
49 to 1075), and approached significance for fat mass
(binteraction = 1107 g, 95% CI 2346 to 132), with greater
benefits for men previously on long-term ADT. At 6 months,
the intervention effects on chair rise time 1.5 s (95% CI
2.5 to 0.5), whole-body lean mass 824 g (95% CI 8 to
1640), ASM mass 709 g (95% CI 260 to 1158), and fat mass
1377 g (95% CI 2156 to 598) were significant for men
previously on long-term ADT, but not for men on short-term
ADT. At 12 months, the intervention effects for men on
long-term ADT remained significant for the chair rise, with
improved performance (2.0 s, 95% CI 3.0 to 1.0) and
increased ASM (537 g, 95% CI 153 to 921). Time on ADT
did not moderate the exercise effects on muscle strength, nor
did time since ADT cessation moderate any intervention
effects. Similarly, testosterone and baseline values of the
outcome had negligible moderator effects.
Conclusions
Men with PCa previously treated long-term with ADT
respond more favourably to exercise in terms of lower body
muscle performance and body composition (lean and fat
mass, and ASM) than those with short-term ADT exposure.
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Trial
As a result, men who were formerly on long-term androgen
suppression regimens should be especially prescribed exercise
medicine interventions to alleviate residual treatment-related
adverse effects.
Keywords
androgen deprivation therapy, exercise, #PCSM, #Prostate
cancer
Introduction
Androgen deprivation therapy (ADT), in conjunction with
radiotherapy (RT) or prostatectomy or as a stand-alone
treatment, is widely used in men with prostate cancer (PCa)
to delay disease progression and enhance survival [1,2];
however, it is also associated with an array of adverse effects
including a reduction in muscle mass, bone mass and
physical performance, an increase in fat mass, sexual
dysfunction and fatigue, and altered metabolic profile and
cognition [3–7]. Moreover, many men will be on ADT for
extended periods of time and will survive for many years
after the cessation of treatment. We [8–10] and others [11,12]
have shown the beneficial effect of physical exercise as a
countermeasure to these treatment-related toxicities in men
currently undergoing androgen suppression, resulting in an
overall enhancement in physical function and quality of life.
Likewise, we also undertook a year-long exercise trial in long-
term survivors of PCa previously treated with adjuvant ADT
and RT for either 6 or 18 months [13]. Those undertaking
supervised resistance and aerobic exercise experienced
significant improvements in cardiorespiratory fitness, muscle
strength, appendicular skeletal muscle (ASM), and physical
function compared with those supplied with printed
educational material on physical activity. However, given the
magnitude of acute and longer-term changes in muscle and
fat mass [4,14,15], as well as muscle strength and objective
and self-reported physical function with androgen
suppression [16,17], that is, pronounced changes in the initial
stages that persist or worsen while therapy is continued, it is
possible that the exercise response may differ based on the
duration of previous exposure to ADT.
Survival rates in men with PCa have improved dramatically
over the past 40 years, with current relative 5-year relative
survival rates of 90% in the UK [18], 95% in Australia [19]
and 99% in the USA [20], although this is influenced by
disease stage at diagnosis. As a result, men with PCa are
living longer after active treatment including the use of ADT.
In prescribing or referring men with PCa including long-term
survivors to exercise medicine [21], it is imperative for the
clinician and exercise specialist to know what factors may
moderate the response to exercise (e.g. time on ADT) so that
appropriate patients/survivors and specific outcomes (e.g.
reversal of muscle loss and muscle function) can be targeted.
Accordingly, we extended our findings on exercise in long-
term survivors of PCa [13] to explore if time on ADT prior
to undertaking a year-long exercise programme moderates
(i.e. influences) the response to exercise. Given the deleterious
effects of androgen suppression on body composition and
physical function and the anabolic nature of exercise, we
evaluated the exercise response on body composition and
muscle performance in those with previous short-term
exposure (6 months) vs long-term exposure (18 months). In
addition, we examined the moderator effect of baseline
testosterone, time since ADT, and baseline value of the
outcome.
Materials and Methods
Recruitment and Study Procedures
In the present study, we used data from men who
participated in the Trans-Tasman Radiation Oncology Group
(TROG) 03.04 Randomised Androgen Deprivation And
Radiotherapy (RADAR) trial [22,23], and were subsequently
enrolled into a multicentre randomized controlled trial (Perth,
WA; Newcastle, New South Wales, Australia; and Wellington,
New Zealand) that evaluated the effects of a yearlong
resistance and aerobic exercise programme compared to a
control group in which participants received physical activity
advice supported with printed material. The detailed
procedures and main effects of this randomized controlled
trial have been described previously [13]. Briefly, 347 out of
843 men (41.2%) from the RADAR cohort responded to the
letter of invitation from their oncologist and were screened
for eligibility. The men were eligible if they: were previously
treated with ADT and RT; were insufficiently active within
the past 6 months (not meeting 150 min of aerobic and two
resistance training sessions per week); were able to walk
400 m; and had obtained medical clearance from their
physician. Exclusion criteria were bone metastases, acute
illness, or any musculoskeletal, cardiovascular or neurological
disorder that could inhibit or put them at risk when
exercising.
After completion of the baseline assessment, 100 men were
randomly assigned to the exercise or control group in a ratio
of 1:1 by a computer random assignment programme, with
the allocation sequence using the minimization technique,
and stratified according to treatment centre, age (<69, 69–74
and >74 years), original RADAR study arm (6 months ADT
© 2017 The Authors.
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 195
ADT time and exercise response
and RT; 6 months ADT and RT and 18 months of
bisphosphonate; 18 months ADT and RT; and 18 months
ADT and RT and 18 months of bisphosphonate) current level
of testosterone (<3, 3–8, >8 nmol/L), whether disease relapse
occurred, and waist circumference (<120 cm). A total of 51
men had previously undertaken 6 months ADT (exercise,
n = 22; control, n = 29) and 49 men had received ADT for
18 months (exercise, n = 28; control, n = 21). The main
reasons why men were excluded from the study were: not
interested/no further response (n = 85); travel constraints or
proximity to exercise sites (n = 43); illness or existing medical
conditions (n = 41); other commitments/time constraints
(n = 28); and already meeting exercise oncology guidelines
(n = 21) [13]. The study was approved by the Human
Research Ethics Committee and all participants provided
written informed consent. (Clinical Trial Registry number:
ACTRN12609000729224.)
Exercise Programme
A detailed description of the exercise programme is
provided elsewhere [13]. Briefly, men in the exercise
group undertook combined progressive resistance and
aerobic exercise twice a week for 6 months in small
groups under direct supervision of an exercise physiologist,
with sessions lastly approximately 1 h. Twice per week
was the chosen intervention frequency to facilitate
recruitment and adherence to the programme, based on
our previous experience in undertaking exercise trials in
men with PCa [8,9], and complied with current exercise
and cancer guidelines for resistance training from the
American College of Sports Medicine [24] and Exercise
and Sports Science Australia [25]. The resistance exercises
included chest press, seated row, shoulder press, triceps
extension, leg press, leg extension, leg curl, and abdominal
crunches, with loading progressing from 12- to 6-
repetition maximum (RM) for two to four sets per
exercise. Aerobic exercises (cycling, walking or jogging)
were included for 20–30 min at 70–85% of maximum
heart rate and perceived exertion at 11–13 on the Borg
Rating of Perceived Exertion Scale (6–20 points). In
addition, participants were instructed to complete two
aerobic exercise sessions per week at home. The exercise
programme was identical across the various training sites.
During months 7–12, the exercise group received a home-
based exercise programme supported by a booklet with
detailed information on resistance, aerobic and flexibility
exercises that replicated the supervised sessions.
The control group received a pedometer and a modified
educational booklet with the general recommendation to
perform 150 min per week of moderate intensity physical
activity for the 12 months. During the course of the study,
participants of both groups were encouraged to maintain
their customary dietary patterns.
Outcome and Moderator Assessments
A moderator is a variable that affects the direction and/or
strength of the relation between an independent variable and
a dependent or outcome variable [26] and, in the case of a
clinical trial, identifies which patients or subgroup of patients
will benefit from the intervention [27]. The moderating effect
of time on ADT (6 vs 18 months) was based on
randomization in the RADAR study [22]. Outcomes were
assessed at baseline, 6 months and 12 months. For all
participants, lower extremity performance was assessed using
the repeated chair rise test, in which the men were timed to
rise to a standing position five times, as fast as possible,
without using their hands for support. Participants from the
Western Australian site (n = 57), who were assessed in the
Exercise Medicine Research Institute at Edith Cowan
University which has extensive assessment and testing
infrastructure, undertook additional measurements of muscle
strength and body composition. Dynamic muscle strength
was determined for the chest press and leg press using the 1-
RM method [28]. Whole-body lean and fat mass were
assessed using dual-energy X-ray absorptiometry (Hologic
Discovery A, Waltham, MA, USA), with ASM mass derived
from the sum of upper limb and lower limb lean mass [29].
Total testosterone was assessed by an accredited laboratory.
Other Measures
Demographic and clinical data were collected by self-report
and medical records, respectively. Height and weight were
assessed using a stadiometer and electronic scales,
respectively, with body mass index calculated from weight in
kg divided by height in m2. Physical activity was assessed
using the Leisure Score Index of the Godin Leisure-Time
Exercise Questionnaire [30] and nutritional status was
assessed using the Mini Nutritional Assessment (MNA) [31].
Statistical Analyses
The sample size estimate in this report was based on
projected changes in cardiorespiratory fitness for the RADAR
exercise trial [13] and not for the moderator effect of ADT
time which was a secondary analysis from the trial. Data were
analysed using IBM SPSS version 24 (IBM Corp., Armonk, NY,
USA). Between-group differences in baseline characteristics
were assessed using independent t-tests for continuous data
and the chi-squared test for categorical data, and a group 9
time repeated measures ANOVA for change over time (baseline,
6 and 12 months) for measures such as the MNA and
testosterone. An intention-to-treat approach was used for all
exercise trial analyses. In line with our previous work [13,32],
analyses were conducted after a likelihood imputation of
missing values (expected maximization). Although the main
effects on the outcomes have been published previously [13],
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we included these analyses to facilitate the interpretation of
the moderator effects. Generalized estimating
equation analyses with an exchangeable correlation structure
were applied to simultaneously evaluate the exercise
intervention effects on the outcomes at 6 and 12 months. We
added intervention, time and their interaction as independent
variables into the regression model, adjusting for the baseline
value of the outcome [33]. Regression coefficients (b) and
95% CIs are presented, indicating the between-group
differences in the outcome variable, expressed in their unit of
measurement.
Potential moderating effects of ADT time, baseline
testosterone, time since ADT cessation, and baseline value of
the outcome were examined by adding the moderator and its
interaction term with the intervention as independent
variables within the generalized estimating equation models,
separately for each potential moderator. Regression
coefficients of the interaction term (binteraction) and 95% CIs
indicate the difference in intervention effects between
moderator subgroups. Related to the small sample size,
stratified analyses for each subgroup were conducted in case
the P value of the interaction term was ≤0.10.
Results
Demographic and clinical characteristics of the 100
participants have been published previously [13,32]. In brief,
participants’ mean (SD) age was 71.7 (6.4) years, and their
mean (SD) height was 170.6 (8.4) cm, weight was 85.2 (12.2)
kg, Gleason score was 7.6 (0.9), and number of comorbidites
was 1.5 (1.4). The characteristics of the 57 participants from
the Western Australian site who undertook all assessments in
this analysis and form the vast majority of the results are
shown in Table 1. Of these 57 participants, 29 had previously
undertaken short-term ADT (exercise, n = 12; control, n =
17) and 28 had been on long-term ADT (exercise, n = 16;
control, n = 12). The mean (SD) age of these 57 participants
was 72.6 (6.9) years, and they had a mean interval since ADT
of 40.6 (15.9) months. There was no difference in any
baseline characteristic between the exercise and the control
group or between those previously on short-term and long-
term ADT for either the full cohort of 100 participants or for
the 57 participants from the Western Australia site
(Table S1). Further, there was no difference between short-
term and long-term ADT users for any of the outcome
measures at baseline. Exercise attendance was 77% and 73%
for the full cohort and for the participants from the Western
Australia site, respectively.
For the full cohort of 100 men, there was no change in
nutritional status between the two groups as determined by
the MNA (group 9 time interaction P = 0.279) although
there was for the Western Australia site (interaction P =
0.015); however, in follow-up tests the change was only an
increase of 1 point in the control group from 27.6 to 28.6 (P
= 0.021). For either the full cohort or those from the Western
Australia site there was no change in the MNA when
analysed by duration of ADT (interaction P = 0.342 and
0.234, respectively). In addition, there was no change in
testosterone levels over the 12-month period for either the
exercise or control groups (n = 100, interaction P = 0.233; n
= 57, interaction P = 0.251), or when analysed as short- and
long-term ADT groups (n = 100, interaction P = 0.303; n =
57, interaction P = 0.807).
Compared with the control group, the exercise intervention
significantly reduced chair rise time and improved chest press
strength at 6 and 12 months, and improved leg press and ASM
at 6 months (Table 2). For chair rise time, the between-group
difference was 1.0 s (95% CI 1.7 to 0.2), favouring the
exercise group (net reduction in time to perform the task) at
6 months, and 1.4 s (95% CI 2.1 to 0.6) at 12 months. For
chest press strength the between-group difference favouring the
exercisers at 6 and 12 months was 3.1 kg (95% CI 1.1 to 5.0)
and 4.2 kg (95% CI 1.0 to 7.3), respectively. In a similar fashion,
the between-group difference for leg press strength was 13.5 kg
(95% CI 0.2 to 26.7) and for ASM 463 g (95% CI 108 to 818) at
6 months, while at 12 months leg press strength and ASM
approached significance at 15.8 kg (95% CI 1.8 to 33.3) and
238 g (95% CI 47 to 534), respectively. No significant overall
intervention effects were found for total body lean and fat mass.
Table 1 Demographic and clinical characteristics of participants from the
Western Australia site (n = 57).
Exercise
(n = 28)
Control
(n = 29)
P
Age, years 73.0 (5.2) 72.2 (8.4) 0.679
Height, cm 172.0 (6.1) 170.5 (6.7) 0.374
Weight, kg 87.8 (12.2) 84.4 (10.6) 0.282
BMI, kg/m2 29.7 (4.4) 29.1 (3.3) 0.539
Tertiary education, n (%) 9 (33) 6 (22) 0.362
Currently employed, n (%) 3 (11) 7 (24) 0.104
Married, n (%) 21 (75) 20 (74) 0.937
Current smoker, n (%) 0 (0) 0 (0)
ADT duration, n (%)
6 months 12 (43) 17 (59) 0.234
18 months 16 (57) 12 (41)
T stage, n (%)
T2 12 (43) 15 (52) 0.619
T3 16 (57) 14 (48)
Gleason score n (%) >7 15 (54) 11 (48) 0.374
Time since ADT, months 38.0 (17.7) 43.1 (13.9) 0.229
Testosterone, nmol/L 12.8 (8.5) 14.3 (7.2) 0.448
≥8 nmol/L 20 (71) 23 (82) 0.342
MNA* 28.3 (2.2) 27.6 (2.0) 0.247
Godin LSI† 24.3 (18.9) 21.8 (19.9) 0.638
Number of comorbidities‡ 1.6 (1.4) 1.5 (1.6) 0.751
BMI, body mass index; ADT, androgen deprivation therapy; LSI, Leisure Score Index;
MNA, Mini Nutritional Assessment; Values are the mean (SD) unless stated otherwise.
*Malnourished <17, undernourished 17–23.5, well-nourished >23.5. †Moderate-to
strenuous LSI ≥ 24 classed as active and LSI ≤ 23 classed as insufficiently active.
‡Cardiovascular disease, hypertension, diabetes, osteoporosis, and dyslipidemia.
© 2017 The Authors.
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ADT time and exercise response
Time on ADT significantly moderated the exercise
intervention effects on chair rise (binteraction = 1.3s, 95% CI
= 2.6 to 0.0), whole-body lean mass (binteraction = 1194 g,
95% CI 234 to 2153) and ASM mass (binteraction = 562 g, 95%
CI 49 to 1075), and approached significance for fat mass
(binteraction = 1107 g, 95% CI 2346 to 132), with larger
benefits for men on previous long-term ADT (Table 3). At
6 months, the net intervention effects on chair rise time 1.5
s (95% CI 2.5 to 0.5), whole-body lean mass 824 g (95%
CI 8 to 1640), ASM mass 709 g (95% CI 260 to 1158), and
fat mass 1377 g (95% CI 2156 to 598) were significant
for men previously on long-term ADT, but not for men on
short-term ADT. That is, previous long-term users had a
reduced time to rise repeatedly from a chair (~12.2%),
increased their lean mass (~1.4%) and ASM mass (~2.7%),
and had a reduction in fat mass (~5.8%) compared with
controls. At 12 months, intervention effects for men on long-
term ADT remained significant for the chair rise with
improved performance (2.0 s, 95% CI 3.0 to 1.0) and
increased ASM (537 g, 95% CI 153 to 921), equivalent to
~16.3% and ~2.1% compared with controls. Time on ADT
did not influence the exercise effect on muscle strength.
Men with higher baseline testosterone levels had larger
reductions in chair rise time (binteraction = 0.1s, 95% CI 0.2
to 0.0 [Table 4]), such that for every nmol/L higher
testosterone level the reduction in chair rise time was 0.1 s.
Baseline whole-body fat mass moderated the intervention
effects on whole-body fat mass (binteraction = 0.14 g, 95% CI
0.00; 0.27), such that intervention-induced reductions in
whole-body fat mass were smaller in men with higher fat
mass at baseline. No other significant moderator effects were
found for baseline testosterone, time since ADT cessation,
and baseline outcome values.
Discussion
The exploratory study produced two important findings: (1)
time on ADT moderated the exercise effect on body
composition with increases in whole-body lean mass at
6 months and appendicular lean mass at 6 and 12 months,
and reduced fat mass at 6 months, in men who had previously
undergone long-term ADT (18 months) but not for those who
had undergone short-term ADT (6 months), and (2) previous
ADT duration modified the effect on lower extremity
performance with an improvement in chair rise time in former
long-term ADT users at 6 and 12 months. These results
suggest that men previously treated with long-term ADT
respond more favourably to exercise medicine interventions to
counteract deficits in lower extremity performance and
detrimental changes in lean and fat mass. This is a key
message for inclusion in PCa survivorship care plans.
A reduction in lean mass and increase in fat mass are well-
known adverse effects of ADT [4,7,14,15] and may not beTa
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reversed after treatment cessation [34]. For instance, van
Londen et al. [14] reported declines in lean mass of ~0.9 kg
and an increase in fat mass of ~1.5 kg after 12 months in
men on acute ADT, when changes in body composition are
more pronounced, with smaller but still significant gains in
fat mass and loss in lean mass in those on chronic ADT.
Similarly, in men initiating ADT, we have previously reported
a loss in lean mass of 1.4 kg and an increase in fat mass of
2.3 kg after 9 months [4]. Exercise in these men, specifically
resistance exercise, is a strategy to counter the marked
catabolic effects on skeletal muscle [7,9] and when short- and
long-term former ADT users are combined there was a
significant increase of ~0.5 kg in ASM at 6 months
(supervised portion of the 12-month programme) [13];
however, this effect was influenced by ADT time with a
substantial exercise effect on lean mass only in former long-
term ADT users of ~0.8 kg at 6 months and ~0.9 kg at
12 months with a significant increase in ASM of 0.7 kg and
0.5 kg at 6 and 12 months, respectively, with no change in
former short-term ADT users. Although most men in the
study had recovered testosterone by commencement of the
intervention, some remained with low levels (<8 nmol/L)
[35]; however, testosterone levels did not influence the
intervention effects on lean mass, nor did time since ADT
cessation or baseline values. The exercise effect appears to be
clearly more marked in previous long-term ADT users, with
substantial gains in lean mass and ASM, and they may
benefit the most when embarking on a resistance and aerobic
exercise programme. Moreover, these changes partially offset
the adverse effects in lean mass that result from ADT and are
likely to be clinically meaningful for the patient and assist in
the prevention of sarcopenia.
Our previous work in men currently undergoing ADT
indicates that there is a negligible effect of exercise, either
resistance exercise alone [8] or resistance combined with
aerobic exercise [9], on fat mass. Similarly, in the present
study, when short- and long-term former ADT users were
combined, the intervention had no effect on fat mass;
however, at 6 months there was a moderating effect of ADT
time, with a substantial reduction of 1.4 kg in long-term
users (equivalent to ~6% net reduction in fat mass). This
change substantially reverses gains in fat mass observed with
ADT which, apart from being statistically significant, may be
considered to be clinically meaningful. We previously noted
an effect of ADT time in men undergoing a 12-week
resistance and aerobic exercise programme, where there was
an adjusted group difference between current short-
(<6 months) and long-term (>6 months) ADT users of
~0.9 kg, where the short-term group had a significant within-
group increase of ~0.6 kg and the long-term ADT users a
significant within-group decrease of 0.4 kg [36]. Taken
together, the present study and our previous work [36]
indicates that duration of treatment, in both current and
Table 3 Moderating effect of androgen deprivation therapy time (short-term, 6 months vs long-term, 18 months), and subsequent stratified analysis in
case of significant moderation.
Moderating effect of ADT
time
Intervention effects for short-term ADT Intervention effects for long-term ADT
b (95% CI) P 6 months 12 months 6 months 12 months
b (95% CI) b (95% CI) b (95% CI) b (95% CI)
Chair rise*, s 1.3 (2.6 to 0.0) 0.05 0.3 (1.4 to 0.8) 0.7 (1.9 to 0.5) 1.5 (2.5 to 0.5)‡ 2.0 (3.0 to 1.0)‡
Chest press†, kg 0.4 (4.8 to 5.5) 0.89    
Leg press†, kg 6.0 (11.6 to 34.5) 0.68    
Whole-body lean mass†, g 1194 (234 to 2153) 0.02 309 (935 to 316) 362 (1055 to 331) 824 (8 to 1640)‡ 903 (28 to 1835)§
Whole-body fat mass†, g 1107 (2346 to 132) 0.08 752 (239 to 1742) 389 (587 to 1366) 1377 (2156 to 598)‡ 13 (946 to 921)
ASM†, g 562 (49 to 1075) 0.04 192 (264 to 648) 93 (483 to 296) 709 (260 to 1158)‡ 537 (153 to 921)‡
ADT, androgen deprivation therapy; ASM, appendicular skeletal muscle. *n = 98. †n = 57. ‡P ≤ 0.05, §0.05 < P ≤ 0.10.
Table 4 Moderating effects of baseline testosterone, time since androgen deprivation therapy, and baseline value of the outcome.
Baseline testosterone, nmol/L Time since ADT, months Baseline outcome value
b (95% CI) P b (95% CI) P b (95% CI) P
Chair rise (s)* –0.1 (0.2 to 0.0) 0.03 0.0 (0.0 to 0.1) 0.11 0.2 (0.2 to 0.5) 0.32
Chest Press (kg)† 0.2 (0.1 to 0.5) 0.23 0.0 (0.2 to 0.2) 0.70 0.1 (0.1 to 0.3) 0.23
Leg press (kg)† 0.6 (2.4 to 1.2) 0.50 0.0 (0.8 to 0.8) 0.97 0.2 (–0.5 to 0.2) 0.31
Whole-body Lean mass (g)† 60 (18 to 137) 0.13 12 (45 to 21) 0.49 0.0 (0.1 to 0.1) 0.95
Whole-body Fat mass (g)† 60 (142 to 21) 0.15 18 (17 to 52) 0.32 0.1 (0.0 to 0.3) 0.04
ASM (g)† 17 (42 to 76) 0.58 12 (30 to 6) 0.21 0.0 (0.1 to 0.1) 0.97
ADT, androgen deprivation therapy; ASM, appendicular skeletal muscle. *n = 98. †n = 57. Results are unadjusted.
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former users of ADT, may influence the effects on the body
fat response to exercise and should be considered when
discussing the benefits of exercise to patients, given the
increased metabolic risk factors associated with ADT [6].
As expected, the intervention had a significant effect on
lower extremity performance and upper and lower body
muscle strength; however, although there was no moderating
effect on muscle strength, there was a moderating effect on
chair rise time, with a substantial improvement in
performance (decreased time) at 6 and 12 months in those
with previous exposure to long-term androgen suppression.
This effect on chair rise performance was not influenced by
chair rise baseline values. Repeated chair rise performance is
not only a measure of muscle strength and power but also
balance and coordination [37,38]. Moreover, in older people,
lower extremity function is associated with functional
limitations and subsequent mobility disability [39], as well
as mortality [40]. Former long-term users of ADT, therefore,
appear to gain the most benefit from exercise on lower
extremity performance which may provide a greater safety
margin for prevention of mobility-related disability. The
values observed after 6 and 12 months in the long-term
ADT group are in alignment with a previously reported
minimally important clinical difference of ~1.7 s in older
patients with chronic obstructive pulmonary disease [41]
and, as such, we would consider the change in our patients
to not only be statistically significant but also clinically
important.
It is not readily apparent why former long-term ADT users
would have a better response to exercise compared with
short-term users. There were no differences at baseline
between the short- and longer-term ADT users for any
clinical/demographic characteristic, including testosterone
levels. Moreover, there was no difference at baseline in the
outcome variables of muscle performance and body
composition. As a result, the moderating effect of ADT time
was not attributable to the long-term group having lower
initial values and hence more room for improvement
(increased responsiveness to exercise) based on the ‘law of
initial values’ [42]. There was also no significant difference in
the number of training sessions attended between the short-
term and long-term group. Regarding testosterone levels,
although testosterone recovery after cessation of treatment is
dependent on duration of ADT [43], given the length of time
since cessation of treatment in the present study, most men
had recovered testosterone levels to within the normal or
borderline range, and baseline testosterone was not a
moderator of muscle strength or body composition. In
addition, there was no change in testosterone levels over the
12-month period. In any event, if there was a difference in
testosterone recovery with it being delayed in the long-term
group then this would favour the short-term ADT group and
not the long-term group.
It is possible that differences in nutritional status over the
course of the intervention could have influenced the results,
augmenting the response to exercise; however, there was no
change in nutritional status over the course of the exercise
trial in either the short-term or long-term group, nor was
there a significant change in physical activity as determined
by the Godin LSI. It is possible, however, that more sensitive
measures of nutrition such as serial 4-day or 7-day dietary
records and physical activity using accelerometers may have
detected differences between the groups that could partially
explain the results found. Lastly, possible differential effects
based on duration of ADT use on skeletal muscle androgen
receptors [44,45] and endocrinological factors, such as IGF-1
[46] may be implicated in the divergent responsiveness to
exercise. Alternatively, it may be that former long-term ADT
users had more deficits than shorter-term users that are not
detected by the measurement techniques employed, and
which respond more to an exercise stimulus. This would
suggest that there are unrecognized longer-term consequences
of hormone suppression than currently appreciated.
The present study has several strengths and limitations that
are worthy of comment. Firstly, only patients at the Western
Australia site underwent the muscle strength and body
composition assessment, and this may have limited our ability
to detect a moderating effect of ADT time for muscle
strength; however, the moderating effect for muscle strength
was negligible and unlikely to be of any clinical importance.
Secondly, men undertaking exercise had, on average,
undergone ADT >3 years previously; however, time since
ADT cessation within the group did not moderate any
intervention effects. Thirdly, our study sample was relatively
small and the results should therefore be confirmed in future
studies. Lastly, the participants were volunteers for an exercise
trial and met specific inclusion criteria, and therefore may not
be representative of all men previously treated with ADT.
The strengths of the study were that we evaluated a well-
characterized cohort of older men previously treated with
ADT from the TROG 03.04 RADAR trial [13,22], who were
long-term PCa survivors. Both upper and lower body strength
were assessed by the 1-RM test in addition to lower extremity
performance and, in using dual X-ray absorptiometry, we
were able not only to assess whole-body lean mass and fat
mass but also to evaluate ASM mass. Lastly, the men
participated in a year-long exercise trial that comprised a
supervised and then a home-based component which
enhances the translatability in the clinical/community setting.
In conclusion, men previously treated long-term with ADT
responded more favourably to a resistance and aerobic
exercise programme in terms of lower extremity performance
and body composition than those with previous short-term
ADT exposure. As a result, although all men currently or
previously on ADT should be undertaking exercise, men who
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were formerly on long-term androgen suppression regimens
should be especially prescribed exercise medicine
interventions to alleviate residual treatment-related adverse
effects due to their enhanced exercise response. Exercise
guidelines are available for patients with cancer from a
number of major international organizations [24,25,47] and,
in general, recommend that patients avoid inactivity and
accumulate 150 min of moderate-intensity or 75 min of
vigorous-intensity aerobic activity, or an equivalent
combination, and undertake at least two resistance or
strength training sessions per week, similar to the
intervention prescribed in the present study. Detailed exercise
recommendations (including rationale and programming
considerations) for men with PCa that are applicable to those
with localized or advanced disease including men with bone
metastases have recently been published [48] and provide an
excellent platform for prescribing exercise medicine in this
population.
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